|
|
|
|
Delaware
|
|
001-36570
|
|
45-4488360
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
ZSAN
|
The Nasdaq Stock Market
|
Parameter
|
ZOTRIP (Single Dose)
|
Open-Label
|
|
Long-Term
|
|||
Placebo
|
M207 3.8 mg
|
M207 3.8 mg
|
|
(n = 77)
|
(n = 82)
|
(5,617 migraine attacks*)
|
|
Pain Freedom at 2 hours
|
14%
|
42%
|
44%
|
Pain Relief at 2 hours
|
57%
|
81%
|
81%
|
Sustained Pain Freedom 2-24 hour
|
10%
|
32%
|
38%
|
Sustained Pain Freedom 2-48 hour
|
9%
|
27%
|
35%
|
Sustained Pain Relief 2-24 hour
|
38%
|
68%
|
70%
|
Sustained Pain Relief 2-48 hour
|
33%
|
63%
|
65%
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION
|
||
|
|
|
|
||
Date: June 15, 2020
|
|
|
By:
|
|
/s/ Christine Matthews
|
|
|
|
|
|
Name: Christine Matthews
|
|
|
|
|
|
Title: Chief Financial Officer
|